83) Anti-tumor necrosis factor (anti-TNF) biologics are effective in the treatment of rheumatoid arthritis (RA); however, it is still not clear whether this treatment promotes the development of malignancies such as lymphoma. |
PMID:24252020 DOI:10.3109/14397595.2013.844389 |
2015 Modern rheumatology |
* Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series. |
- Anti-tumor necrosis factor (anti-TNF) biologics are effective in the treatment of rheumatoid arthritis (RA); however, it is still not clear whether this treatment promotes the development of malignancies such as lymphoma. Human T-lymphotropic virus type 1 (HTLV-1), which is a causative agent of adult T-cell lymphoma (ATL), is prevalent in Japan. Many HTLV-1-positive patients with RA are assumed to exist; however, there have thus far been no reports on the effect of anti-TNF biologics on HTLV-1-positive patients. We analyzed the response to treatment with anti-TNF biologics and change of HTLV-1 markers in two cases of RA. The two cases showed no response based on the European League Against of Rheumatism response criteria 60-96 weeks after administration of anti-TNF biologics (infliximab and etanercept). No signs of ATL were observed and HTLV-1 markers, such as proviral load and clonality of HTLV-1-infected cells, showed no significant change in either of two cases. Therefore, treatment with anti-TNF biologics did not induce activation of HTLV-1, although the effect on RA was not as effective as in HTLV-1-negative patients in this limited study. Further long-term study with a greater number of patients is necessary to clarify the safety and efficacy of anti-TNF biologics in HTLV-1-positive patients with RA. |
(1)36 cells | (17)6 size | (33)3 lysis | (49)2 progression, |
(2)23 suppressor | (18)6 suppression | (34)3 onset | (50)2 recurred |
(3)22 progression | (19)6 tissue | (35)3 targeting | (51)2 recurrence |
(4)20 necrosis | (20)6 with | (36)3 to | (52)2 regression |
(5)19 *null* | (21)5 angiogenesis | (37)3 types | (53)2 response |
(6)17 growth | (22)5 initiating | (38)2 1 | (54)2 samples, |
(7)15 cell | (23)5 suppressive | (39)2 activity | (55)2 site |
(8)14 was | (24)5 volume | (40)2 burden | (56)2 size, |
(9)12 and | (25)4 model | (41)2 classification | (57)2 that |
(10)11 development | (26)4 sites | (42)2 composed | (58)2 the |
(11)11 in | (27)4 suppressors | (43)2 expression | (59)2 tissue, |
(12)11 of | (28)3 effects | (44)2 heterogeneity | (60)2 tissues |
(13)7 microenvironment | (29)3 excision | (45)2 invasion | (61)2 treatment |
(14)6 formation | (30)3 extension | (46)2 is | |
(15)6 promotion | (31)3 had | (47)2 metastasis | |
(16)6 samples | (32)3 local | (48)2 mice |
add keyword